<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2023-435</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-8024</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГИНЕКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GYNECOLOGY</subject></subj-group></article-categories><title-group><article-title>Целевые группы молодых женщин для выбора трехфазной комбинированной гормональной контрацепции</article-title><trans-title-group xml:lang="en"><trans-title>Target groups of young women for triphasic combined hormonal contraception</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5541-3767</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузнецова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuznetsova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузнецова Ирина Всеволодовна - д.м.н., профессор, заместитель генерального директора по научно-исследовательской работе.</p><p>117593, Москва, Большая Марфинская ул., д. 2</p></bio><bio xml:lang="en"><p>Irina V. Kuznetsova - Dr. Sci. (Med.), Professor, Deputy General Director for Research.</p><p>2, Bolshaya Marfinskaya St., Moscow, 117593</p></bio><email xlink:type="simple">ms.smith.ivk@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Клиника «Витбиомед+»<country>Россия</country></aff><aff xml:lang="en">Vitbiomed+ LLC<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>20</day><month>01</month><year>2024</year></pub-date><volume>0</volume><issue>23</issue><fpage>243</fpage><lpage>249</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кузнецова И.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Кузнецова И.В.</copyright-holder><copyright-holder xml:lang="en">Kuznetsova I.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/8024">https://www.med-sovet.pro/jour/article/view/8024</self-uri><abstract><p>Гормональная контрацепция широко применяется для предохранения от нежелательной беременности и представлена большим числом препаратов, позволяющих персонализировать выбор для каждой женщины. Варианты комбинированных оральных контрацептивов (КОК) включают не только разные по качественному составу препараты, но и модификации режима приема. В числе нетривиальных режимов заслуживает внимание трехфазное дозирование активных компонентов, позволяющее добиться снижения прогестагенной нагрузки при сохранении контрацептивной эффективности. Этот подход важен при назначении КОК женщинам, у которых ранее были отмечены или потенциально могут появиться побочные реакции на прием прогестагенов. Выделение целевых групп женщин с предрасположенностью к прогестаген-зависимым побочным эффектам помогает сделать корректное назначение КОК и увеличить приверженность к использованию контрацептивного метода. Так, к отказу от КОК могут приводить изменения характеристик кровотечений на фоне приема гормональной контрацепции. За исключением пациенток, которым КОК назначаются с дополнительной лечебной целью для контроля ритма или обильности менструаций, женщины ожидают сохранения привычной картины своего цикла и негативно реагируют на любые его изменения, отклонения от нормы. Между тем профиль кровотечений во время использования гормональной контрацепции может существенно меняться. При оценке воздействия противозачаточного средства на маточные кровотечения важны такие характеристики, как обильность и предсказуемость маточных кровотечений. В данном аналитическом обзоре представлены группы молодых женщин, для которых первичное назначение трехфазных КОК может быть наилучшим вариантом выбора.</p></abstract><trans-abstract xml:lang="en"><p>Hormonal contraception is widely used to prevent unintended pregnancies and is represented by a large number of drugs that allow to personalize the choice of contraceptives for each woman. Combined oral contraceptive (COC) variants include not only drugs that differ in qualitative composition, but also modifications of the dosage regimen. Among the non-trivial regimens are triphasic active ingredient dosing that enables to achieve a reduction in progestogen burden while maintaining contraceptive efficacy. This approach is important in prescribing COCs to women who have previously experienced or may potentially experience adverse reactions to progestogens. Identification of target groups of women predisposed to progestogen-dependent side effects helps to correctly prescribe COCs and improve adherence to the contraceptive method. Thus, changes in bleeding characteristics during the use of hormonal contraceptives may lead to refusal of COCs. With the exception of patients who are prescribed COCs for additional therapeutic purposes to control the menstrual cycle rhythmicity and intensity, women expect that they keep the usual pattern of their cycle and react negatively to any changes or deviations from the reference ranges. Meanwhile, the bleeding profile during the use of hormonal contraceptives can change significantly. Characteristics such as the intensity and predictability of uterine bleeding are important for the assessment of the effect of a contraceptive on uterine bleeding. This analytical review presents groups of young women for whom initial use of triphasic COCs may be the best choice.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гормональная контрацепция</kwd><kwd>трехфазные комбинированные оральные контрацептивы</kwd><kwd>этинилэстрадиол</kwd><kwd>дезогестрел</kwd><kwd>аменорея</kwd><kwd>вагинальная сухость у молодых женщин</kwd><kwd>кровотечения прорыва</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hormonal contraception</kwd><kwd>triphasic combined oral contraceptives</kwd><kwd>ethinyl estradiol</kwd><kwd>desogestrel</kwd><kwd>amenorrhea</kwd><kwd>vaginal dryness in young women</kwd><kwd>breakthrough bleeding</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Haakenstad A, Angelino O, Irvine CMS, Bhutta ZA, Bienhoff K, Bintz C et al. Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10348):295–327. https://doi.org/10.1016/S0140-6736(22)00936-9.</mixed-citation><mixed-citation xml:lang="en">Haakenstad A, Angelino O, Irvine CMS, Bhutta ZA, Bienhoff K, Bintz C et al. Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10348):295–327. https://doi.org/10.1016/S0140-6736(22)00936-9.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Regidor PA. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018;9(77):34628–34638. https://doi.org/10.18632/oncotarget.26015.</mixed-citation><mixed-citation xml:lang="en">Regidor PA. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018;9(77):34628–34638. https://doi.org/10.18632/oncotarget.26015.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11(1):41–47. https://doi.org/10.5812/ijem.4158.</mixed-citation><mixed-citation xml:lang="en">Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11(1):41–47. https://doi.org/10.5812/ijem.4158.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Carr BR. Cycle control with desogestrel-containing oral contraceptives-comparison of a monophasic and triphasic regimen. Int J Fertil Menopausal Stud. 1993;38(5):274–279. Available at: https://pubmed.ncbi.nlm.nih.gov/8298666.</mixed-citation><mixed-citation xml:lang="en">Carr BR. Cycle control with desogestrel-containing oral contraceptives-comparison of a monophasic and triphasic regimen. Int J Fertil Menopausal Stud. 1993;38(5):274–279. Available at: https://pubmed.ncbi.nlm.nih.gov/8298666.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Van Vliet HA, Grimes DA, Lopez LM, Schulz KF, Helmerhorst FM. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2011;2011(11):CD003553. https://doi.org/10.1002/14651858.CD003553.pub3.</mixed-citation><mixed-citation xml:lang="en">Van Vliet HA, Grimes DA, Lopez LM, Schulz KF, Helmerhorst FM. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2011;2011(11):CD003553. https://doi.org/10.1002/14651858.CD003553.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bastianelli C, Farris M, Bruni V, Brosens I, Benagiano G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 4. Effects on uterine and cervical epithelia. Expert Rev Clin Pharmacol. 2020;13(2):163–182. https://doi.org/10.1080/17512433.2020.1721280.</mixed-citation><mixed-citation xml:lang="en">Bastianelli C, Farris M, Bruni V, Brosens I, Benagiano G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 4. Effects on uterine and cervical epithelia. Expert Rev Clin Pharmacol. 2020;13(2):163–182. https://doi.org/10.1080/17512433.2020.1721280.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Моргунов РА, Кравченко ЕН. Лечебные эффекты комбинированных оральных контрацептивов. Мать и дитя в Кузбассе. 2017;(2):4–8. Режим доступа: https://mednauki.ru/index.php/MD/article/view/35.</mixed-citation><mixed-citation xml:lang="en">Morgunov RA, Kravchenko EN. Therapeutic effects of combined oral contraceptives. Mother and Baby in Kuzbass. 2017;2(69):4–8. (In Russ.) Available at: https://mednauki.ru/index.php/MD/article/view/35.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Access J Contracept. 2016;7:43–52. https://doi.org/10.2147/OAJC.S85565.</mixed-citation><mixed-citation xml:lang="en">Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Access J Contracept. 2016;7:43–52. https://doi.org/10.2147/OAJC.S85565.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Munro MG, Critchley HOD, Fraser IS. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408. https://doi.org/10.1002/ijgo.12666.</mixed-citation><mixed-citation xml:lang="en">Munro MG, Critchley HOD, Fraser IS. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408. https://doi.org/10.1002/ijgo.12666.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mishell DR Jr, Guillebaud J, Westhoff C, Nelson AL, Kaunitz AM, Trussell J, Davis AJ. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception. 2007;75(1):11–15. https://doi.org/10.1016/j.contraception.2006.08.012.</mixed-citation><mixed-citation xml:lang="en">Mishell DR Jr, Guillebaud J, Westhoff C, Nelson AL, Kaunitz AM, Trussell J, Davis AJ. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception. 2007;75(1):11–15. https://doi.org/10.1016/j.contraception.2006.08.012.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Creinin MD, Vieira CS, Westhoff CL, Mansour DJA. Recommendations for standardization of bleeding data analyses in contraceptive studies. Contraception. 2022;112:14–22. https://doi.org/10.1016/j.contraception.2022.05.011.</mixed-citation><mixed-citation xml:lang="en">Creinin MD, Vieira CS, Westhoff CL, Mansour DJA. Recommendations for standardization of bleeding data analyses in contraceptive studies. Contraception. 2022;112:14–22. https://doi.org/10.1016/j.contraception.2022.05.011.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 µg versus &gt;20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;2013(8):CD003989. https://doi.org/10.1002/14651858.CD003989.pub5.</mixed-citation><mixed-citation xml:lang="en">Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 µg versus &gt;20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;2013(8):CD003989. https://doi.org/10.1002/14651858.CD003989.pub5.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol. 1996;174(2):628–632. https://doi.org/10.1016/s0002-9378(96)70440-4.</mixed-citation><mixed-citation xml:lang="en">Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol. 1996;174(2):628–632. https://doi.org/10.1016/s0002-9378(96)70440-4.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Seif MW, Diamond K, Nickkho-Amiry M. Obesity and menstrual disorders. Best Pract Res Clin Obstet Gynaecol. 2015;29(4):516–527. https://doi.org/10.1016/j.bpobgyn.2014.10.010.</mixed-citation><mixed-citation xml:lang="en">Seif MW, Diamond K, Nickkho-Amiry M. Obesity and menstrual disorders. Best Pract Res Clin Obstet Gynaecol. 2015;29(4):516–527. https://doi.org/10.1016/j.bpobgyn.2014.10.010.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Marom-Haham L, Shulman A. Cigarette smoking and hormones. Curr Opin Obstet Gynecol. 2016;28(4):230–235. https://doi.org/10.1097/GCO.0000000000000283.</mixed-citation><mixed-citation xml:lang="en">Marom-Haham L, Shulman A. Cigarette smoking and hormones. Curr Opin Obstet Gynecol. 2016;28(4):230–235. https://doi.org/10.1097/GCO.0000000000000283.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Both S, Lew-Starowicz M, Luria M, Sartorius G, Maseroli E, Tripodi F et al. Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM). J Sex Med. 2019;16(11):1681–1695. https://doi.org/10.1016/j.jsxm.2019.08.005.</mixed-citation><mixed-citation xml:lang="en">Both S, Lew-Starowicz M, Luria M, Sartorius G, Maseroli E, Tripodi F et al. Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM). J Sex Med. 2019;16(11):1681–1695. https://doi.org/10.1016/j.jsxm.2019.08.005.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Снарская ЕС, Семенчак ЮА. Склероатрофический лихен аногенитальной локализации: клинико-морфологические, дифференциально-диагностические особенности и комплексный метод лечения. РМЖ. Медицинское обозрение. 2019;(12):9–13. Режим доступа: https://www.rmj.ru/articles/dermatologiya/Skleroatroficheskiy_lihen_anogenitalynoy_lokalizacii_kliniko-morfologicheskie_differencialyno-diagnosticheskie_osobennosti_i_kompleksnyy_metod_lecheniya/?ysclid=lozepiln2j60418825.</mixed-citation><mixed-citation xml:lang="en">Snarskaya ES, Semenchak YuA. Anogenital lichen sclerosus: clinicopathologic, differential diagnostic features and complex treatment method. RMJ. Medical Review. 2019;(12):9–13. (In Russ.) Available at: https://www.rmj.ru/articles/dermatologiya/Skleroatroficheskiy_lihen_anogenitalynoy_lokalizacii_kliniko-morfologicheskie_differencialyno-diagnosticheskie_osobennosti_i_kompleksnyy_metod_lecheniya/?ysclid=lozepiln2j60418825.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Herbison AE. A simple model of estrous cycle negative and positive feedback regulation of GnRH secretion. Front Neuroendocrinol. 2020;57:100837. https://doi.org/10.1016/j.yfrne.2020.100837.</mixed-citation><mixed-citation xml:lang="en">Herbison AE. A simple model of estrous cycle negative and positive feedback regulation of GnRH secretion. Front Neuroendocrinol. 2020;57:100837. https://doi.org/10.1016/j.yfrne.2020.100837.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Sondheimer SJ. Oral contraceptives: mechanism of action, dosing, safety, and efficacy. Cutis. 2008;81(1 Suppl.):19–22. Available at: https://pubmed.ncbi.nlm.nih.gov/18338654.</mixed-citation><mixed-citation xml:lang="en">Sondheimer SJ. Oral contraceptives: mechanism of action, dosing, safety, and efficacy. Cutis. 2008;81(1 Suppl.):19–22. Available at: https://pubmed.ncbi.nlm.nih.gov/18338654.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M et al. Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(5):1413–1439. https://doi.org/10.1210/jc.2017-00131.</mixed-citation><mixed-citation xml:lang="en">Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M et al. Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(5):1413–1439. https://doi.org/10.1210/jc.2017-00131.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kyvernitakis I, Kostev K, Nassour T, Thomasius F, Hadji P. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int. 2017;28(1):291–297. https://doi.org/10.1007/s00198-016-3714-4.</mixed-citation><mixed-citation xml:lang="en">Kyvernitakis I, Kostev K, Nassour T, Thomasius F, Hadji P. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int. 2017;28(1):291–297. https://doi.org/10.1007/s00198-016-3714-4.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hadji P, Colli E, Regidor PA. Bone health in estrogen-free contraception. Osteoporos Int. 2019;30(12):2391–2400. https://doi.org/10.1007/s00198019-05103-6.</mixed-citation><mixed-citation xml:lang="en">Hadji P, Colli E, Regidor PA. Bone health in estrogen-free contraception. Osteoporos Int. 2019;30(12):2391–2400. https://doi.org/10.1007/s00198019-05103-6.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Dombrowski S, Jacob L, Hadji P, Kostev K. Oral contraceptive use and fracture risk – a retrospective study of 12,970 women in the UK. Osteoporos Int. 2017;28(8):2349–2355. https://doi.org/10.1007/s00198-017-4036-x.</mixed-citation><mixed-citation xml:lang="en">Dombrowski S, Jacob L, Hadji P, Kostev K. Oral contraceptive use and fracture risk – a retrospective study of 12,970 women in the UK. Osteoporos Int. 2017;28(8):2349–2355. https://doi.org/10.1007/s00198-017-4036-x.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">DiVasta AD, Feldman HA, Beck TJ, LeBoff MS, Gordon CM. Does hormone replacement normalize bone geometry in adolescents with anorexia nervosa? J Bone Miner Res. 2014;29(1):151–157. https://doi.org/10.1002/jbmr.2005.</mixed-citation><mixed-citation xml:lang="en">DiVasta AD, Feldman HA, Beck TJ, LeBoff MS, Gordon CM. Does hormone replacement normalize bone geometry in adolescents with anorexia nervosa? J Bone Miner Res. 2014;29(1):151–157. https://doi.org/10.1002/jbmr.2005.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Almstedt HC, Cook MM, Bramble LF, Dabir DV, LaBrie JW. Oral contraceptive use, bone mineral density, and bone turnover markers over 12 months in college-aged females. J Bone Miner Metab. 2020;38(4):544–554. https://doi.org/10.1007/s00774-019-01081-1.</mixed-citation><mixed-citation xml:lang="en">Almstedt HC, Cook MM, Bramble LF, Dabir DV, LaBrie JW. Oral contraceptive use, bone mineral density, and bone turnover markers over 12 months in college-aged females. J Bone Miner Metab. 2020;38(4):544–554. https://doi.org/10.1007/s00774-019-01081-1.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Grandi G, Cagnacci A, Volpe A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2014;10(1):1–10. https://doi.org/10.1517/17425255.2013.844229.</mixed-citation><mixed-citation xml:lang="en">Grandi G, Cagnacci A, Volpe A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2014;10(1):1–10. https://doi.org/10.1517/17425255.2013.844229.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Lethaby A, Wise MR, Weterings MA, Bofill Rodriguez M, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2(2):CD000154. https://doi.org/10.1002/14651858.CD000154.pub3.</mixed-citation><mixed-citation xml:lang="en">Lethaby A, Wise MR, Weterings MA, Bofill Rodriguez M, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2(2):CD000154. https://doi.org/10.1002/14651858.CD000154.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">De La Cruz MS, Buchanan EM. Uterine Fibroids: Diagnosis and Treatment. Am Fam Physician. 2017;95(2):100–107. Available at: https://pubmed.ncbi.nlm.nih.gov/28084714.</mixed-citation><mixed-citation xml:lang="en">De La Cruz MS, Buchanan EM. Uterine Fibroids: Diagnosis and Treatment. Am Fam Physician. 2017;95(2):100–107. Available at: https://pubmed.ncbi. nlm.nih.gov/28084714.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501–1512. https://doi.org/10.1111/1471-0528.14640.</mixed-citation><mixed-citation xml:lang="en">Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501–1512. https://doi.org/10.1111/1471-0528.14640.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Burnett M, Lemyre M. No. 345-Primary Dysmenorrhea Consensus Guideline. J Obstet Gynaecol Can. 2017;39(7):585–595. https://doi.org/10.1016/j.jogc.2016.12.023.</mixed-citation><mixed-citation xml:lang="en">Burnett M, Lemyre M. No. 345-Primary Dysmenorrhea Consensus Guideline. J Obstet Gynaecol Can. 2017;39(7):585–595. https://doi.org/10.1016/j.jogc.2016.12.023.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol. 1994;170(5):1499–1507. https://doi.org/10.1016/s0002-9378(94)05011-8.</mixed-citation><mixed-citation xml:lang="en">Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol. 1994;170(5):1499–1507. https://doi.org/10.1016/s0002-9378(94)05011-8.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Archer DF, Timmer CJ, Lammers P. Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol. Fertil Steril. 1994;61(4):645–651. https://doi.org/10.1016/s0015-0282(16)56640-0.</mixed-citation><mixed-citation xml:lang="en">Archer DF, Timmer CJ, Lammers P. Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol. Fertil Steril. 1994;61(4):645–651. https://doi.org/10.1016/s0015-0282(16)56640-0.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Lortscher D, Admani S, Satur N, Eichenfield LF. Hormonal Contraceptives and Acne: A Retrospective Analysis of 2147 Patients. J Drugs Dermatol. 2016;15(6):670–674. Available at: https://pubmed.ncbi.nlm.nih.gov/27272072.</mixed-citation><mixed-citation xml:lang="en">Lortscher D, Admani S, Satur N, Eichenfield LF. Hormonal Contraceptives and Acne: A Retrospective Analysis of 2147 Patients. J Drugs Dermatol. 2016;15(6):670–674. Available at: https://pubmed.ncbi.nlm.nih.gov/27272072.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Katz HI, Kempers S, Akin MD, Dunlap F, Whiting D, Norbart TCJ. Effect of a desogestrel-containing oral contraceptive on the skin. Eur J Contracept Reprod Health Care. 2000;5:248–255. https://doi.org/10.1080/13625180008500411.</mixed-citation><mixed-citation xml:lang="en">Katz HI, Kempers S, Akin MD, Dunlap F, Whiting D, Norbart TCJ. Effect of a desogestrel-containing oral contraceptive on the skin. Eur J Contracept Reprod Health Care. 2000;5:248–255. https://doi.org/10.1080/13625180008500411.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Kranzlin HT, Nap MA. The effect of a phasic oral contraceptive containing Desogestrel on seborrhea and acne. Eur J Contracept Reprod Health Care. 2006;11(1):6–13. https://doi.org/10.1080/13625180500252638.</mixed-citation><mixed-citation xml:lang="en">Kranzlin HT, Nap MA. The effect of a phasic oral contraceptive containing Desogestrel on seborrhea and acne. Eur J Contracept Reprod Health Care. 2006;11(1):6–13. https://doi.org/10.1080/13625180500252638.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
